Home

A Novel BERberine derivative for Malignant MESothelioma

Asbestos exposure is the main risk factor for malignant mesothelioma. This rare and lethal cancer affects the mesothelium: the protective thin layer of tissue that covers many of the internal organs of the body. The tumour has a long latency period taking 20 to 50 years to appear. Because of its aggressiveness and highly resilience, researchers are on the hunt for newer and better treatment strategies. This is indeed the main goal of BERMES: developing a novel molecule with a disruptive mechanism of action that has shown activity in this hard-to-treat tumour.

 

WATCH VIDEO ►